Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.11% | 36.71 | 0.9% | $1248.49m | |
| JNJ | Johnson & Johnson | -0.23% | 160.28 | 0.7% | $1180.84m | |
| MRK | Merck & Co., Inc. | 1.47% | 83.38 | 0.7% | $793.32m | |
| ABBV | AbbVie, Inc. | -1.02% | 110.49 | 1.9% | $741.62m | |
| LLY | Eli Lilly & Co. | 2.20% | 190.79 | 1.1% | $736.86m | |
| BMY | Bristol-Myers Squibb Co. | 0.82% | 66.56 | 1.0% | $715.48m | |
| AZN | AstraZeneca Plc | 0.10% | 51.34 | 1.2% | $669.12m | |
| RPRX | Royalty Pharma Plc | 1.37% | 51.95 | 0.2% | $220.52m | |
| VTRS | Viatris, Inc. | -1.50% | 17.05 | 0.0% | $200.69m | |
| ARCT | Arcturus Therapeutics Holdings, Inc. | -4.14% | 59.69 | 0.0% | $197.04m | |
| NVS | Novartis AG | 1.07% | 95.63 | 0.2% | $176.60m | |
| GSK | GlaxoSmithKline Plc | 0.80% | 38.47 | 0.2% | $144.27m | |
| SNY | Sanofi | 0.73% | 49.39 | 0.2% | $114.02m | |
| RGEN | Repligen Corp. | 1.52% | 215.47 | 6.9% | $81.99m | |
| NVO | Novo Nordisk A/S | 1.41% | 72.03 | 0.1% | $74.66m |
Company Profile
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.